Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

Mikko Purhonen, Mikael Tatun, Kevin Hung, Oda Tafjord, Shady Adnan-Awad, Perttu Koskenvesa, Sanna Siitonen, Kimmo Porkka, Satu Mustjoki, Signe Danielsson, Henrik Hjorth-Hansen, Ulla Olsson-Strömberg, Takashi Kumagai, Shinya Kimura, David M Ross, Oscar E. Brück

Blood (2024) 144 (Supplement 1): 1780.

https://doi.org/10.1182/blood-2024-207253

Published: 2024

Journal Articles

Single-Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation

Blood (2023) 142 (Supplement 1): 3146.

https://doi.org/10.1182/blood-2023-185630

Published: 2023

Journal Articles

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Blood (2023) 142 (1): 73–89.

https://doi.org/10.1182/blood.2022016896

Published: 2023

Includes: Supplemental data

Journal Articles

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Blood (2022) 140 (Supplement 1): 818–820.

https://doi.org/10.1182/blood-2022-162252

Published: 2022

Journal Articles

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Jani Huuhtanen, Jason Theodoropoulos, BSc, Rebecca Warfvinge, MSc, Andreas Burchert, MD, Tiina Kasanen, Jay Klievink, MSc, Shady Adnan Awad, MD, Olli Dufva, MD, Mette Ilander, PhD, Taina Jaatinen, Ulla Olsson-Strömberg, MD PhD, Henrik Hjorth-Hansen, MD, Göran Karlsson, PhD, Harri Lähdesmäki, PhD, Anna Kreutzman, PhD, Satu Mustjoki, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139134

Published: 2020

Journal Articles

Health-Related Quality of Life Outcomes in Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Dasatinib and Low Dose Pegylated Interferon

Henrik Hjorth-Hansen, MD, Satu Mustjoki, MD PhD, Ulla Olsson-Strömberg, MD PhD, Jesper Stentoft, Professor, dr.MD, Fabio Efficace, PhD, Hemming Johansson, PhD, Yvonne Brandberg, PhD

Blood (2018) 132 (Supplement 1): 4260.

https://doi.org/10.1182/blood-2018-99-111714

Published: 2018

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

KIT signaling is dispensable for human mast cell progenitor development

Joakim S. Dahlin, Maria Ekoff, Jennine Grootens, Liza Löf, Rose-Marie Amini, Hans Hagberg, Johanna S. Ungerstedt, Ulla Olsson-Strömberg, Gunnar Nilsson

Blood (2017) 130 (16): 1785–1794.

https://doi.org/10.1182/blood-2017-03-773374

Published: 2017

Includes: Supplemental data

Journal Articles

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Rebecca Warfvinge, Linda Geironson, Mikael N. E. Sommarin, Stefan Lang, Christine Karlsson, Teona Roschupkina, Leif Stenke, Jesper Stentoft, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, Satu Mustjoki, Shamit Soneji, Johan Richter, Göran Karlsson

Blood (2017) 129 (17): 2384–2394.

https://doi.org/10.1182/blood-2016-07-728873

Published: 2017

Includes: Supplemental data

Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Blood (2016) 128 (22): 789.

https://doi.org/10.1182/blood.V128.22.789.789

Published: 2016

Journal Articles

No Increased Prevalence of Malignancies Among First-Degree Relatives of Patients with Chronic Myeloid Leukemia - Data from Population-Based Swedish Registries

Niklas Gunnarsson, MD, Martin Höglund, MD PhD, Leif Stenke, MD PhD, Fredrik Sandin, MSc, Magnus Bjorkholm, Arta Dreimane, MD PhD, Mats Lambe, MD PhD, Berit Markevärn, MD, Ulla Olsson-Strömberg, MD PhD, Hans Wadenvik, MD PhD, Johan Richter, MD, Anders Själander, MD PhD

Blood (2016) 128 (22): 1896.

https://doi.org/10.1182/blood.V128.22.1896.1896

Published: 2016

Journal Articles

Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Blood (2016) 128 (22): 627.

https://doi.org/10.1182/blood.V128.22.627.627

Published: 2016

Journal Articles

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

Anna Kreutzman, PhD, Perttu Koskenvesa, MD, Kasanen Tiina, Ulla Olsson-Strömberg, MD PhD, Jesper Stentoft, MD PhD, Leif Stenke, MD PhD, Lene Udby, MD, Bjorn T. Gjertsen, MD PhD, Kourosh Lotfi, MD, Berit Markevän, MD PhD, Jeroen Janssen, MD, Tim Brümmendorf, MD, Johan Richter, MD, Henrik Hjorth-Hansen, MD PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 3069.

https://doi.org/10.1182/blood.V128.22.3069.3069

Published: 2016

Journal Articles

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

Mohamed El Missiry, MD MSc, Shady Adnan, MD MSc, Hanna Rajala, MD PhD, Ahmed Al-Samadi, DDS, PhD, Marja Ekblom, Berit Markevän, MD PhD, Ingbritt Åstrand-Grundström, Maren Wold, Birgitte Ravn Juhl, MD dr.MDsci, Ole Weis Bjerrum, MD DMSc, Inger Haulin, Kimmo Porkka, MD PhD, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, MD PhD, Satu Mustjoki, MD PhD

Blood (2015) 126 (23): 4027.

https://doi.org/10.1182/blood.V126.23.4027.4027

Published: 2015

Journal Articles

Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia

Niklas Gunnarsson, MD, Martin Hoglund, MD PhD, Leif Stenke, MD PhD, Solveig Wallberg Jonsson, MD PhD, Fredrik Sandin, PhD, Magnus Bjorkholm, MD PhD, Arta Dreimane, MD PhD, Mats Lambe, MD PhD, Berit Markevarn, MD, Ulla Olsson-Stromberg, MD PhD, Hans Wadenvik, MD PhD, Johan Richter, MD PhD, Anders Sjalander, MD PhD

Blood (2015) 126 (23): 1586.

https://doi.org/10.1182/blood.V126.23.1586.1586

Published: 2015

Journal Articles

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Blood (2015) 126 (23): 343.

https://doi.org/10.1182/blood.V126.23.343.343

Published: 2015

Journal Articles

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Blood (2014) 124 (21): 812.

https://doi.org/10.1182/blood.V124.21.812.812

Published: 2014

Journal Articles

Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Niklas Gunnarsson, MD, Stenke Leif, MD PhD, Martin Höglund, MD PhD, Fredrik Sandin, PhD, Magnus Björkholm, MD PhD, Arta Dreimane, MD PhD, Mats Lambe, MD PhD, Berit Markevärn, MD, Ulla Olsson-Strömberg, MD PhD, Johan Richter, MD PhD, Hans Wadenvik, MD PhD, Jonas Wallvik, MD PhD, Anders Själander, MD PhD

Blood (2014) 124 (21): 154.

https://doi.org/10.1182/blood.V124.21.154.154

Published: 2014

Journal Articles

Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study

Blood (2014) 124 (21): 151.

https://doi.org/10.1182/blood.V124.21.151.151

Published: 2014

Journal Articles

Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Blood (2013) 122 (21): 2731.

https://doi.org/10.1182/blood.V122.21.2731.2731

Published: 2013

NARROW

Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

Single-Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Health-Related Quality of Life Outcomes in Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Dasatinib and Low Dose Pegylated Interferon

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

KIT signaling is dispensable for human mast cell progenitor development

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

No Increased Prevalence of Malignancies Among First-Degree Relatives of Patients with Chronic Myeloid Leukemia - Data from Population-Based Swedish Registries

Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study

Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only